Problems in mesothelioma diagnosis

Histopathology

Volumn 54, Issue 1, 2009, Pages 55-68

  Addis, Bruce ^a,b   Roche, Heather ^a  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^b SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

Diagnosis; Immunohistochemistry; Mesothelioma; Pathology

Indexed keywords

DESMIN; EPITHELIAL MEMBRANE ANTIGEN; PROTEIN P53;

CANCER CLASSIFICATION; DESMOPLASTIC MESOTHELIOMA; DIFFERENTIAL DIAGNOSIS; EPITHELOID MESOTHELIOMA; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LYMPHOMA; MALIGNANT MESOTHELIOMA; MELANOMA; MESOTHELIOMA; OSTEOSARCOMA; PLEURA TUMOR; PLEURAL FIBROSIS; PRIORITY JOURNAL; REVIEW; SARCOMATOID MESOTHELIOMA; SENSITIVITY AND SPECIFICITY; SYNOVIAL SARCOMA; THYMOMA; VASCULAR TUMOR;

DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; MESOTHELIOMA; PLEURAL NEOPLASMS;

EID: 58449088744     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2008.03178.x     Document Type: Review

References (101)

1. Bianchi C, Bianchi T. Malignant mesothelioma: global incidence and relationship with asbestos. Ind. Health. 2007 45 379 387.
2. McElvenny DM, Darnton AJ, Price MJ, Hodgson JT. Mesothelioma mortality in Great Britain from 1968 to 2001. Occup. Med. 2005 55 79 87.
3. Peto J, Hodgson JT, Matthews FE, Jones JR. Continuing increase in mesothelioma mortality in Britain. Lancet 1995 345 535 539.
4. McDonald JC, McDonald AD. The epidemiology of mesothelioma in historical context. Eur. Resp. J. 1996 9 1932 1942.
5. Rusch VW. Diagnosis and treatment of pleural mesothelioma. Semin. Surg. Oncol. 1990 6 279 285.
6. United Kingdom Health and Safety Executive. Health and safety statistics 2006/2007. November 2007. Available at: http://www.hse.gov.uk/statistics/ overall/hssh0607.pdf, page 8. Last accessed: 12 November 2008.
7. Hodgson JT, McElvenny DM, Darnton AJ, Price MJ, Peto J. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br. J. Cancer 2005 92 587 593.
8. van Ruth S, Baas P, Zoetmulder FAN. Surgical treatment of malignant pleural mesothelioma: a review. Chest 2003 123 551 561.
9. Muers MF, Stephens RJ, Fisher P et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 2008 371 1685 1694.
10. Ismail-Khan R, Robinson LA, Williams CC, Garrett CR, Bepler G, Simon GR. Malignant pleural mesothelioma: a comprehensive review. Cancer Control 2006 13 255 263.
11. Benamore RE, O'Doherty MJ, Entwistle JJ. Use of imaging in the management of malignant pleural mesothelioma. Clin. Radiol. 2005 60 1237 1247.
12. van Gelder T, Hoogsteden HC, Vandenbroucke JP, van der Kwast TH, Planteydt HT. The influence of the diagnostic technique on the histopathological diagnosis in malignant mesothelioma. Archows Archiv A Pathol. Anat. 1991 418 315 317.
13. Kradin RL, Mark EJ. Distinguishing benign mesothelial hyperplasia from neoplasia: a practical approach. Semin. Diagn. Pathol. 2006 23 4 14.
14. Suster S, Moran C. Malignant mesothelioma: current status of histopathologic diagnosis and molecular profile. Expert Rev. Mol. Diagn. 2005 5 715 723.
15. Whitaker D, Henderson DW, Shilkin KB. The concept of mesothelioma in situ: implications for diagnosis and histogenesis. Semin. Diagn. Pathol. 1992 9 151 161.
16. Henderson DW, Shilkin KB, Whitaker D. Reactive mesothelial hyperplasia vs mesothelioma, including mesothelioma in situ. Am. J. Clin. Pathol. 1998 110 397 404.
17. Cury PM, Butcher DN, Corrin B, Nicholson AG. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis. J. Pathol. 1999 189 251 257.
18. Attanoos RL, Griffin A, Gibbs AR. The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2. Histopathology 2003 43 231 238.
19. Saad RS, Cho P, Liu YL, Silverman JF. The value of epithelial membrane antigen expression in separating benign mesothelial proliferation from malignant mesothelioma. Diagn. Cytopathol. 2005 32 156 159.
20. King J, Thatcher N, Pickering C, Hasleton P. Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports. Histopathology 2006 49 561 568.
21. Churg A, Roggli V, Colby T et al. The separation of benign and malignant mesothelial proliferations. Am. J. Surg. Pathol. 2000 24 1183 1200.
22. Bogers J, Jacobs W, Segers K, Van Daele A, Weyler J, Van Marck E. Stereological evaluation of malignant mesothelioma versus benign pleural hyperplasia. Pathol. Res. Pract. 1996 192 10 14.
23. Ayers JG, Crocker JG, Skilbeck NQ. Differentiation of malignant from normal and reactive mesothelial cells by the argyrophil technique for nucleolar organiser region associated proteins. Thorax 1988 43 366 370.
24. Sington JD, Morris LS, Nicholson AG, Coleman N. Assessment of cell cycle state may facilitate the histopathological diagnosis of malignant mesothelioma. Histopathology 2003 42 498 502.
25. Kumaki F, Kawai T, Churg A et al. Expression of telomerase reverse transcriptase (TERT) in malignant mesotheliomas. Am. J. Surg. Pathol. 2002 26 365 370.
26. McCaughey WTE, Colby TV, Battifora H et al. Diagnosis of diffuse malignant mesothelioma: experience of a US/Canadian mesothelioma panel. Mod. Pathol. 1991 4 342 352.
27. Cagle PT, Churg A. Differential diagnosis of benign and malignant mesothelial proliferations on pleural biopsies. Arch. Pathol. Lab. Med. 2005 129 1421 1427.
28. Corson JM. Pathology of mesothelioma. Thorac. Surg. Clin. 2004 14 447 460.
29. Mangano WE, Cagle PT, Churg A, Vollmer RT, Roggli VL. The diagnosis of desmoplastic malignant mesothelioma and its distinction from fibrous pleurisy: a histological and immunohistochemical analysis of 31 cases including p53 immunostaining. Am. J. Clin. Pathol. 1998 110 191 199.
30. Colby TV. Malignancies in the lung and pleura mimicking benign processes. Semin. Diagn. Pathol. 1995 12 30 44.
31. Wilson GE, Hasleton PS, Chatterjee AK. Desmoplastic malignant mesothelioma: a review of 17 cases. J. Clin. Pathol. 1992 45 295 298.
32. Hammar SP, Bockus DE, Remington FL, Rohrbach KA. Mucin-positive mesotheliomas: a histochemical, immunohistochemical, and ultrastructural comparison with mucin-secreting pulmonary adenocarcinomas. Ultrastruct. Pathol. 1996 20 293 325.
33. Miettinen M, Sarlomo-Rikala M. Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura. Am. J. Surg. Pathol. 2003 27 150 158.
34. King JE, Thatcher N, Pickering CAC, Hasleton PS. Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data. Histopathology 2006 48 223 232.
35. Ordonez NG. What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update. Hum. Pathol. 2007 38 1 16.
36. Suster S, Moran CA. Applications and limitations of immunohistochemistry in the diagnosis of malignant mesothelioma. Adv. Anat. Pathol. 2006 13 316 329.
37. Chu AY, Litzky LA, Pasha TL, Acs G, Zhang PJ. Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod. Pathol. 2005 18 105 110.
38. Mimura T, Ito A, Sakuma T et al. Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma. Cancer 2007 109 933 938.
39. Ordonez NG. D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma. Hum. Pathol. 2005 36 372 380.
40. Ordonez NG. Immunohistochemical diagnosis of epithelioid mesothelioma: an update. Arch. Pathol. Lab. Med. 2005 129 1407 1414.
41. Muller AM, Franke FE, Muller KM. D2-40: a reliable marker in the diagnosis of pleural mesothelioma. Pathobiology 2006 73 50 54.
42. Ordonez NG. Podoplanin: a novel diagnostic immunohistochemical marker. Adv. Anat. Pathol. 2006 13 83 88.
43. Padgett DM, Cathro HP, Wick MR, Mills SE. Podoplanin is a better immunohistochemical marker for sarcomatoid mesothelioma than calretinin. Am. J. Surg. Pathol. 2008 32 123 127.
44. Comin CE, Dini S, Novelli L, Santi R, Asirelli G, Messerini L. h-caldesmon, a useful positive marker in the diagnosis of pleural malignant mesothelioma, epithelioid type. Am. J. Surg. Pathol. 2006 30 463 469.
45. Comin CE, Saieva C, Messerini L. h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary. Am. J. Surg. Pathol. 2007 31 1139 1148.
46. Llinares K, Escande F, Aubert S et al. Diagnostic value of MUC4 immunostaining in distinguishing epithelial mesothelioma and lung adenocarcinoma. Mod. Pathol. 2004 17 150 157.
47. Ordonez NG. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod. Pathol. 2003 16 192 197.
48. Ordonez NG. Application of mesothelin immunostaining in tumor diagnosis. Am. J. Surg. Pathol. 2003 27 1418 1428.
49. Kushitani K, Takeshima Y, Amatya VJ, Furonaka O, Sakatani A, Inai K. Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma. Pathol. Int. 2007 57 190 199.
50. Marchevsky AM. Application of immunohistochemistry to the diagnosis of malignant mesothelioma. Arch. Pathol. Lab. Med. 2008 132 397 401.
51. Li Q, Bavikatty N, Michael CW. The role of immunohistochemistry in distinguishing squamous cell carcinoma from mesothelioma and adenocarcinoma in pleural effusions. Semin. Diagn. Pathol. 2006 23 15 19.
52. Pu RT, Pang Y, Michael CW. Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions. Diagn. Cytopathol. 2008 36 20 25.
53. Attanoos RL, Gibbs AR. 'Pseudomesotheliomatous' carcinomas of the pleura: a 10-year analysis of cases from the Environmental Lung Disease Research Group, Cardiff. Histopathology 2003 43 444 452.
54. Barnetson RJ, Burnett RA, Downie I, Harper CM, Roberts F. Immunohistochemical analysis of peritoneal mesothelioma and primary and secondary serous carcinoma of the peritoneum: antibodies to estrogen and progesterone receptors are useful. Am. J. Clin. Pathol. 2006 125 67 76.
55. Ordonez NG, Myhre M, Mackay B. Clear cell mesothelioma. Ultrastruct. Pathol. 1996 20 331 336.
56. Dessy E, Falleni M, Braidotti P, Del Curto B, Panigalli T, Pietra GG. Unusual clear cell variant of epithelioid mesothelioma. Arch. Pathol. Lab. Med. 2001 125 1588 1590.
57. Ordonez NG. The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study. Hum. Pathol. 2004 35 697 710.
58. Butnor KJ, Nicholson AG, Allred DC et al. Expression of renal cell carcinoma-associated markers erythropoietin, CD10 and renal cell carcinoma marker in diffuse malignant mesothelioma and metastatic renal cell carcinoma. Arch. Pathol. Lab. Med. 2006 130 823 827.
59. Attanoos RL, Goddard H, Thomas ND, Jasani B, Gibbs AR. A comparative immunohistochemical study of malignant mesothelioma and renal cell carcinoma: the diagnostic utility of Leu-M1, Ber EP4, Tamm-Horsfall protein and thrombomodulin. Histopathology 1995 27 361 366.
60. Attanoos RL, Thomas DH, Gibbs AR. Synchronous diffuse malignant mesothelioma and carcinomas in asbestos-exposed individuals. Histopathology 2004 43 387 392.
61. Attanoos RL, Webb R, Dojcinov SD, Gibbs AR. Malignant epithelioid mesothelioma: anti-mesothelial marker expression correlates with histological pattern. Histopathology 2001 39 584 588.
62. Mayall FG, Gibbs AR. The histology and immunohistochemistry of small cell mesothelioma. Histopathology 1992 20 47 51.
63. Shia J, Erlandson RA, Klimstra DS. Deciduoid mesthelioma: a report of 5 cases and literature review. Ultrastruct. Pathol. 2002 26 355 363.
64. Nascimento AG, Keeney GL, Fletcher CD. Deciduoid peritoneal mesothelioma. An unusual phenotype affecting young females. Am. J. Surg. Pathol. 1994 18 439 445.
65. Shanks JH, Harris M, Banerjee SS et al. Mesotheliomas with deciduoid morphology: a morphologic spectrum and a variant not confined to young females. Am. J. Surg. Pathol. 2000 24 285 294.
66. Ordonez NG. Epithelial mesothelioma with deciduoid features: report of four cases. Am. J. Surg. Pathol. 2000 24 816 823.
67. Serio G, Scattone A, Pennella A et al. Malignant deciduoid mesothelioma of the pleura: report of two cases with long survival. Histopathology 2002 40 348 352.
68. Ordonez NG. Mesothelioma with rhabdoid features: an ultrastructural and immunohistochemical study of 10 cases. Mod. Pathol. 2006 19 373 383.
69. Henderson DW. Lymphohistiocytoid mesothelioma: a rare lymphomatoid variant of predominantly sarcomatoid mesothelioma. Ultrastruct. Pathol. 1988 12 367 384.
70. Khalidi HS, Medeiros LJ, Battifora H. Lymphohistiocytoid mesothelioma: an often misdiagnosed variant of sarcomatoid mesothelioma. Am. J. Clin. Pathol. 2000 113 649 654.
71. Yao DX, Shia J, Erlandson RA, Klimstra DS. Lymphohistiocytoid mesothelioma: a clinical, immunohistochemical and ultrastructural study of four cases and literature review. Ultrastruct. Pathol. 2004 28 213 228.
72. Galateau-Salle F, Attanoos R, Gibbs AR et al. Lymphohistiocytoid variant of malignant mesothelioma of the pleura: a series of 22 cases. Am. J. Surg. Pathol. 2007 31 711 716.
73. Granville L, Laga AC, Allen TC et al. Review and update of uncommon primary pleural tumors: a practical approach to diagnosis. Arch. Pathol. Lab. Med. 2005 129 1428 1443.
74. Kaplan MA, Tazelaar HD, Hayashi T, Schroer KR, Travis WD. Adenomatoid tumors of the pleura. Am. J. Surg. Pathol. 1996 20 1219 1223.
75. Allen TC. Recognition of histopathologic patterns of diffuse malignant mesothelioma in differential diagnosis of pleural biopsies. Arch. Pathol. Lab. Med. 2005 129 1415 1420.
76. Allen TC, Cagle PT, Churg A et al. Localized malignant mesothelioma. Am. J. Surg. Pathol. 2005 29 866 873.
77. English JC, Leslie KO. Pathology of the pleura. Clin. Chest Med. 2006 27 157 180.
78. Attanoos RL, Galateau-Salle F, Gibbs AR, Muller S, Ghandour F, Dojcinov SD. Primary thymic epithelial tumours of the pleura mimicking malignant mesothelioma. Histopathology 2002 41 42 49.
79. Quiox E, Chenard MP, Orion B, Lang-Averous G, Dopff-Kaissling A. A left pleural effusion with a calcified tumoral mass and left hemithoracic uptake on bone scan. Lung Cancer 2001 32 203 205.
80. Okamoto T, Yokota S, Shinkawa K et al. Pleural malignant mesothelioma with osseous cartilaginous and rhabdomyogenic differentiation. Nihon Kokyuki Gakkai Zasshi 1998 36 696 701.
81. Chandak P, Hunt I, Rawlins R, Lucas S, Treasure T. Bone or pleura? Primary pleural osteosarcoma. J. Thorac. Cardiovasc. Surg. 2007 133 587 588.
82. Matono R, Maruyama R, Ide S et al. Extraskeletal osteosarcoma of the pleura: a case report. Gen. Thorac. Cardiovasc. Surg. 2008 56 180 182.
83. Chakravarty K, Saeed IT, Fowler RW. A fatal case of pleural osteosarcoma mimicking mesothelioma in Paget's disease of bone. Rheumatology 2003 42 1578 1579.
84. Essary LR, Vargas SO, Fletcher CD. Primary pleuropulmonary synovial sarcoma: reappraisal of a recently described anatomic subset. Cancer 2002 94 459 469.
85. Rdzanek M, Fresco R, Pass HI, Carbone M. Spindle cell tumors of the pleura: differential diagnosis. Semin. Diagn. Pathol. 2006 23 44 55.
86. Nicholson AG, Goldstraw P, Fisher C. Synovial sarcoma of the pleura and its differentiation from other primary pleural tumours: a clinicopathological and immunohistochemical review of three cases. Histopathology 1998 33 508 513.
87. MIC2) Neuroectodermal/Ewing's sarcoma antigen as an immunohistochemical marker: review of more than 600 tumors and the literature experience. Appl. Immunohistochem. 1994 2 231 240.
88. Amary MF, Berisha F, Bernadi FC et al. Detection of SS18-SSX fusion transcripts in formalin-fixed paraffin-embedded neoplasms: analysis of conventional RT-PCR, qRT-PCR and dual color FISH as diagnostic tools for synovial sarcomas. Mod. Pathol. 2007 20 482 496.
89. Lin BTY, Colby T, Gown A et al. Malignant vascular tumors of the serous membranes mimicking mesothelioma. Am. J. Surg. Pathol. 1996 20 1431 1439.
90. Attanoos RL, Suvarna SK, Rhead E et al. Malignant vascular tumours of the pleura in "asbestos" workers and endothelial differentiation in malignant mesothelioma. Thorax 2000 55 860 863.
91. Zhang PJ, Livolsi VA, Brooks JJ. Malignant epithelioid vascular tumors of the pleura: report of a series and literature review. Hum. Pathol. 2000 31 29 34.
92. Roh MS, Seo JY, Hong SH. Epithelioid angiosarcoma of the pleura: a case report. J. Korean Med. Sci. 2001 16 792 795.
93. Pramesh CS, Madur BP, Raina S, Desai S, Mistry RC. Angiosarcoma of the pleura. Ann. Thorac. Cardiovasc. Surg. 2004 10 187 190.
94. Ritter JH, Mills SE, Nappi O, Wick MR. Angiosarcoma-like neoplasms of epithelial organs: true endothelial tumors or variants of carcinoma? Semin. Diagn. Pathol. 1995 12 270 282.
95. Ascani S, Piccioli M, Poggi S et al. Pyothorax-associated lymphoma: description of the first two cases detected in Italy. Ann. Oncol. 1997 8 1133 1138.
96. Petitjean B, Jardin F, Joly B et al. Pyothorax-associated lymphoma: a peculiar pathological entity derived from B-cells at late stage of differentiation and with occasional aberrant dual B- and T-cell phenotype. Am. J. Surg. Pathol. 2002 26 724 732.
97. Verghese ET, Amer KM, Addis BJ. Pyothorax-associated lymphoma: an unusual variant of an unusual tumour. Histopathology 2007 51 131 133.
98. Nakatsuka S, Yao M, Hoshida Y, Yamaamoto S, Luchi K, Aozasa K. Pyothorax-associated lymphoma: a review of 106 cases. J. Clin. Oncol. 2002 20 4255 4260.
99. Makamichi I, Takakuwa T, Tanio Y, Luchi K, Aozasa K. Pyothorax-associated lymphoma: an unusual case with both T- and B-cell genotypes. Virchows Arch. 2005 447 888 891.
100. Betta PG, Andrion A, Donna A et al. Malignant mesothelioma of the pleura. The reproducibility of the immunohistochemical diagnosis. Pathol. Res. Pract. 1997 193 759 765.
101. Andrion A, Magnani C, Betta PG et al. Malignant mesothelioma of the pleura: interobserver variability. J. Clin. Pathol. 1995 48 856 860.